The oral Ca/calmodulin‐dependent kinase II inhibitor RA608 improves contractile function and prevents arrhythmias in heart failure
Open Access
- 20 July 2020
- journal article
- research article
- Published by Wiley in ESC Heart Failure
- Vol. 7 (5), 2871-2883
- https://doi.org/10.1002/ehf2.12895
Abstract
Aims Excessive activation of Ca/calmodulin‐dependent kinase II (CaMKII) is of critical importance in heart failure (HF) and atrial fibrillation. Unfortunately, lack of selectivity, specificity, and bioavailability have slowed down development of inhibitors for clinical use. We investigated a novel CaMKIIδ/CaMKIIɣ‐selective, ATP‐competitive, orally available CaMKII inhibitor (RA608) on right atrial biopsies of 119 patients undergoing heart surgery. Furthermore, we evaluated its oral efficacy to prevent deterioration of HF in mice after transverse aortic constriction (TAC). Methods and results In human atrial cardiomyocytes and trabeculae, respectively, RA608 significantly reduced sarcoplasmic reticulum Ca leak, reduced diastolic tension, and increased sarcoplasmic reticulum Ca content. Patch‐clamp recordings confirmed the safety of RA608 in human cardiomyocytes. C57BL6/J mice were subjected to TAC, and left ventricular function was monitored by echocardiography. Two weeks after TAC, RA608 was administered by oral gavage for 7 days. Oral RA608 treatment prevented deterioration of ejection fraction. At 3 weeks after TAC, ejection fraction was 46.1 ± 3.7% (RA608) vs. 34.9 ± 2.6% (vehicle), n = 9 vs. n = 12, P < 0.05, ANOVA, which correlated with significantly less CaMKII autophosphorylation at threonine 287. Moreover, a single oral dose significantly reduced inducibility of atrial and ventricular arrhythmias in CaMKIIδ transgenic mice 4 h after administration. Atrial fibrillation was induced in 6/6 mice for vehicle vs. 1/7 for RA608, P < 0.05, 'n − 1' χ 2 test. Ventricular tachycardia was induced in 6/7 for vehicle vs. 2/7 for RA608, P < 0.05, 'n − 1' χ 2 test. Conclusions RA608 is the first orally administrable CaMKII inhibitor with potent efficacy in human myocytes. Moreover, oral administration potently inhibits arrhythmogenesis and attenuates HF development in mice in vivo .Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (387509280), and Sachbeihilfe, MA 1982/7‐1,, MA 1982/5‐1,, WA 2539/7‐1,, WA 2539/5‐1,, WA 2539/4‐1)
- Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
- Universität Regensburg
- Deutsches Zentrum für Herz-Kreislaufforschung
- Deutsche Stiftung für Herzforschung (F/35/15)
This publication has 41 references indexed in Scilit:
- Different subcellular populations of L-type Ca2+ channels exhibit unique regulation and functional roles in cardiomyocytesJournal of Molecular and Cellular Cardiology, 2012
- CaMKII in myocardial hypertrophy and heart failureJournal of Molecular and Cellular Cardiology, 2011
- Tachycardia-Induced Diastolic Dysfunction and Resting Tone in Myocardium From Patients With a Normal Ejection FractionJournal of the American College of Cardiology, 2011
- Reactive Oxygen Species–Activated Ca/Calmodulin Kinase IIδ Is Required for Late I Na Augmentation Leading to Cellular Na and Ca OverloadCirculation Research, 2011
- Epidemiology and risk profile of heart failureNature Reviews Cardiology, 2010
- Differential Cardiac Remodeling in Preload Versus AfterloadCirculation, 2010
- Calcium/Calmodulin-Dependent Protein Kinase II Contributes to Cardiac Arrhythmogenesis in Heart FailureCirculation: Heart Failure, 2009
- Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathwaysJCI Insight, 2009
- Ca/Calmodulin Kinase II Differentially Modulates Potassium CurrentsCirculation: Arrhythmia and Electrophysiology, 2009
- Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channelsJCI Insight, 2006